More work is required to determine whether protection from MS in TYK2P carriers might be predicted based upon the proportion of Tfh-17 cells and/or dual-positive IFN-γ+/IL-17+ CD4+ effector T cells. This evidence concerns the gene CD4 and myeloid sarcoma.